Abstract:Molecularly targeted drugs have yielded significant therapeutic advances in oncogene-driven non-small cell lung cancer (NSCLC), but a majority of patients eventually develop acquired resistance. Recently, the relation between proinflammatory cytokine IL6 and resistance to targeted drugs has been reported. We investigated the functional contribution of IL6 and the other members of IL6 family proinflammatory cytokine pathway to resistance to targeted drugs in NSCLC cells. In addition, we examined the production of these cytokines by cancer cells and cancer-associated fibroblasts (CAF). We also analyzed the prognostic significance of these molecule expressions in clinical NSCLC samples. In NSCLC cells with acquired resistance to targeted drugs, we observed activation of the IL6-cytokine pathway and STAT3 along with epithelial-to-mesenchymal transition (EMT) features. In particular, IL6 family cytokine oncostatin-M (OSM) induced a switch to the EMT phenotype and protected cells from targeted drug-induced apoptosis in OSM receptors (OSMRs)/JAK1/STAT3-dependent manner. The crosstalk between NSCLC cells and CAFs also preferentially activated the OSM/STAT3 pathway via a paracrine mechanism and decreased sensitivity to targeted drugs. The selective JAK1 inhibitor filgotinib effectively suppressed STAT3 activation and OSMR expression, and cotargeting inhibition of the oncogenic pathway and JAK1 reversed resistance to targeted drugs. In the analysis of clinical samples, OSMR gene expression appeared to be associated with worse prognosis in patients with surgically resected lung adenocarcinoma. Our data suggest that the OSMRs/JAK1/STAT3 axis contributes to resistance to targeted drugs in oncogene-driven NSCLC cells, implying that this pathway could be a therapeutic target. (C) 2017 AACR.

Janus Kinase 1 Plays a Critical Role in Mammary Cancer Progression

JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non-Small Cell Lung Cancer.

Figure S2 from JAK1/STAT3 Activation Through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer

The Janus kinase 1 is critical for pancreatic cancer initiation and progression

JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression

IL-6/JAK/STAT3 Signaling in Breast Cancer Metastasis: Biology and Treatment

Nuclear JAK2: Form and Function in Cancer

Regulation of the JAK2-STAT5 Pathway by Signaling Molecules in the Mammary Gland

Deciphering JAK/STAT signaling pathway: A multifaceted approach to tumorigenesis, progression and therapeutic interventions

The JAK/STAT signaling pathway: from bench to clinic

Targeting JAK kinase in solid tumors: emerging opportunities and challenges

Molecular characterization of STAT signaling in inflammation and tumorigenesis

The role of IL-6/JAK2/STAT3 signaling pathway in cancers

JAK1 inactivation promotes proliferation and migration of endometrial cancer cells via upregulating the hypoxia-inducible factor signaling pathway

JAK2 expression is correlated with the molecular and clinical features of breast cancer as a favorable prognostic factor

Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models

Targeting the JAK/STAT pathway in solid tumors

JAK/STAT Signaling and Cervical Cancer: From the Cell Surface to the Nucleus

Rab1A promotes IL-4R/JAK1/STAT6-dependent metastasis and determines JAK1 inhibitor sensitivity in non-small cell lung cancer

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

Dysregulation of JAM-A Plays an Important Role in Human Tumor Progression.